Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selectikine plus local radiotherapy dose-escalation maintenance study in advanced NSCLC
NL-OMON34011Phase 1Not yet recruiting
- Sponsor
- Merck KGaA
- Start
- Mar 2009
- Modality
- Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EMD 521873 in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Primary endpoint: Dose-limiting toxicities. Planned start Mar 2009; status: not yet recruiting.
02
Drugs
EMD 521873
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON34011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34011.